Laxygal (Sodium Picosulfate Monohydrate)

Sodium picosulfate is a pro‑drug that is metabolized by colonic bacteria into an active compound. This metabolite activates enteric nerves, enhancing peristalsis and promoting secretion of water and electrolytes into the intestinal lumen, which softens stool and accelerates its passage.

The appropriate dose of Laxygal is determined by the prescribing healthcare professional based on the patient’s condition, age, and response. Dosage instructions are provided on the product label and must be followed exactly as directed by the prescriber.

Safety data for sodium picosulfate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Laxygal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with osmotic laxatives such as polyethylene glycol, sodium picosulfate acts as a stimulant, producing a quicker onset of bowel movements. It is often preferred for bowel preparation because it requires a smaller volume of fluid, but individual response and tolerability may vary.

Laxygal should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Laxygal is taken orally, usually with a specified amount of water as directed by the prescriber. The tablets or granules are swallowed whole; they should not be chewed, crushed, or dissolved unless the label specifically permits it.

Serious risks include severe dehydration, marked electrolyte disturbances (especially low potassium), and rare allergic reactions. Patients should seek immediate medical attention if they experience persistent diarrhea, dizziness, fainting, or signs of an allergic response.

Laxygal should be avoided in individuals with known or suspected intestinal obstruction, acute abdominal pain of unknown cause, severe inflammatory bowel disease, or hypersensitivity to sodium picosulfate. It is also contraindicated in patients for whom electrolyte balance cannot be safely monitored.